Clinical Edit Criteria

Drug/Drug Class: Megestrol Acetate Clinical Edit
Date: April 18, 2019
Prepared for: MO HealthNet
Prepared by: MO HealthNet

☐ New Criteria ☒ Revision of Existing Criteria

Executive Summary

Purpose: Ensure appropriate and prudent use of megestrol acetate within the MO HealthNet Pharmacy program.

Why was this Issue Selected: Megestrol is a synthetic female hormone belonging to the progesterone family. Megestrol is indicated for palliative treatment of advanced carcinoma of the breast or endometrium. It is also used to stimulate appetite and promote weight gain in patients with muscle wasting due to cancer or in patients with acquired immunodeficiency syndrome (AIDS).

Type of Criteria: ☐ Increased risk of ADE ☒ Non-Preferred Agent
☒ Appropriate Indications

Data Sources: ☒ Only administrative databases ☐ Databases + Prescriber-supplied

Setting & Population

- Drug/drug class for review: Megestrol Acetate
- Age range: All appropriate participants 18 years of age and older
### Approval Criteria

- Appropriate diagnosis – or inferred
  - Malignant neoplasm – breast
  - Malignant neoplasm – uterus
  - Malignant neoplasm – ovaries
  - HIV/AIDS plus cachexia

### Denial Criteria

- Megace ES or Megace 40mg/ml as first line therapy (generic preferred)
- Pregnancy
- Doses exceeding
  - 800mg/day for Megestrol Acetate
  - 625mg/day for Megace ES
- Lack of compliance on first-line therapy regimen
- Lack of appropriate diagnoses
  - Utilization for cachexia in the absence of HIV/AIDS diagnosis

### Required Documentation

<table>
<thead>
<tr>
<th>Laboratory results:</th>
<th>Progress notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MedWatch form:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

### Disposition of Edit

- **Denial:** Exception Code “682” (Clinical Edit)

### References